Penumbra PEN Embolization and Access — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's embolization and access — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's embolization and access — revenue?
- Penumbra (PEN) reported embolization and access — revenue of $120.84M in Q1 2026.
- How has Penumbra's embolization and access — revenue changed year-over-year?
- Penumbra's embolization and access — revenue increased by 23.8% year-over-year, from $97.6M to $120.84M.
- What does embolization and access — revenue mean?
- Total revenue earned from selling neurovascular embolization and vascular access medical devices.
- How do you interpret embolization and access — revenue?
- An increase indicates growing adoption of the company's specialized neurovascular tools and successful expansion within the interventional medical device market. A decrease may signal increased competition, loss of market share, or a slowdown in procedure volumes for these specific clinical applications.
- How does embolization and access — revenue compare across companies?
- Comparable to specialized neurovascular or interventional device revenue segments reported by medical technology peers focusing on stroke and vascular intervention.